With a pulmonary artery systolic pressure of 90 mm Hg, should I start anticoagulation?

Should You Start Anticoagulation with PA Systolic Pressure of 90 mmHg?

The decision to anticoagulate depends entirely on the underlying diagnosis—not the PA pressure itself. A PA systolic pressure of 90 mmHg indicates severe pulmonary hypertension, but anticoagulation is diagnosis-specific and not indicated based on pressure elevation alone.

Critical First Step: Determine the Underlying Cause

You must first classify which type of pulmonary hypertension this patient has, as anticoagulation recommendations differ dramatically:

If This is Acute Pulmonary Embolism (PE):

Yes, start anticoagulation immediately. 1

• Initiate intravenous unfractionated heparin (UFH) without delay, including a weight-adjusted bolus injection if hemodynamically unstable (systolic BP <90 mmHg for >15 minutes) 1
• If hemodynamically stable, prefer LMWH or fondaparinux over UFH 1
• Transition to a NOAC (apixaban, dabigatran, edoxaban, or rivaroxaban) when oral anticoagulation is initiated 1
• Continue therapeutic anticoagulation for >3 months at minimum 1

If This is Chronic Thromboembolic Pulmonary Hypertension (CTEPH):

Yes, lifelong anticoagulation is mandatory. 2, 3

• Vitamin K antagonists (VKAs) targeting INR 2.0-3.0 are the traditional standard 2
• Recent evidence suggests DOACs are equally effective and safe as VKAs (no difference in VTE recurrence, bleeding, or mortality) 3
• Anticoagulation is required regardless of whether the patient undergoes pulmonary endarterectomy 2

If This is Pulmonary Arterial Hypertension (PAH):

Anticoagulation is controversial and depends on PAH subtype:

For Idiopathic PAH (IPAH):

Consider anticoagulation—evidence suggests potential benefit. 4, 5, 6

• Retrospective data from the COMPERA registry showed significantly better 3-year survival in IPAH patients on anticoagulation 4
• Decision analysis models demonstrate a gain of 0.43-0.51 quality-adjusted life years with anticoagulation in IPAH 6
• However, a 2024 meta-analysis found anticoagulation only showed a trend toward reduced mortality (HR 0.86,95% CI 0.73-1.02) without reaching statistical significance 5

For Connective Tissue Disease-Associated PAH (CTD-PAH):

Do NOT routinely anticoagulate—evidence shows harm. 5, 6, 7

• Decision analysis shows a loss of 0.66-1.89 quality-adjusted life years with anticoagulation in CTD-PAH 6
• Increased bleeding risk, particularly gastrointestinal bleeding, outweighs any potential benefit 7
• Exception: Consider anticoagulation only if lupus anticoagulant or anticardiolipin antibodies are present 7

For Other PAH Subtypes:

No clear benefit demonstrated—reserve for standard indications only (atrial fibrillation, documented VTE) 8

Key Clinical Pitfalls to Avoid

1. Do not anticoagulate based on PA pressure alone—the underlying diagnosis determines treatment
2. Do not use NOACs in severe renal impairment or antiphospholipid antibody syndrome 1
3. Do not assume all pulmonary hypertension benefits from anticoagulation—CTD-PAH patients may be harmed 6, 7
4. Do not forget that abnormal PT/PTT is NOT a contraindication to thromboprophylaxis in appropriate clinical contexts 9

Practical Algorithm

1. Confirm the diagnosis: Is this acute PE, CTEPH, or PAH?
2. If acute PE or CTEPH: Start anticoagulation immediately (Class I recommendation)
3. If IPAH: Discuss risks/benefits; consider anticoagulation unless bleeding risk is prohibitive
4. If CTD-PAH: Do NOT anticoagulate unless specific thrombophilic condition present
5. If Group 2 PH (left heart disease) or Group 3 PH (lung disease): Anticoagulate only for standard indications (AF, VTE)

The PA pressure of 90 mmHg tells you the severity but not the treatment—establish the etiology first, then apply diagnosis-specific anticoagulation guidelines.